CellarisBio Secures Patent and Launches MICRO-TAG Platform for Real-Time Drug-Target Engagement
核心洞察
CellarisBio (搜索) received U.S. patent US12510537B2 for its MICRO-TAG (搜索) technology platform and launched its first commercial reagent product line at SLAS 2026.
The MICRO-TAG (搜索) platform represents the first reagent-based system enabling real-time, temperature-series measurement of drug-target engagement directly within cells.
The technology addresses challenging drug targets including membrane proteins (搜索) and transcription factors (搜索) that cannot be reliably studied using traditional biophysical methods.
CellarisBio (搜索) announced the issuance of its flagship U.S. patent covering the MICRO-TAG (搜索) technology platform and the commercial launch of its first MICRO-TAG reagent product line at the SLAS 2026 International Conference & Exhibition in Boston. The newly issued patent, "High Throughput Drug Screening Methods" (US12510537B2), secures foundational intellectual property for MICRO-TAG's real-time cellular target engagement chemistry and workflows.
Novel Technology Platform Addresses Drug Discovery Challenges
MICRO-TAG (搜索) represents the first reagent-based platform to enable real-time, temperature-series measurement of drug-target engagement directly in cells. Built on a novel fluorescence enzyme complementation chemistry that activates only upon intracellular target engagement, the system delivers deep mechanistic insight not accessible through conventional endpoint assays.
The technology is particularly impactful for challenging drug targets—including membrane proteins (搜索) and transcription factors (搜索)—that cannot be reliably studied using traditional biophysical methods such as SPR or MST. The commercial launch follows extensive validation of MICRO-TAG (搜索) technology across 100+ drug targets.
"MICRO-TAG (搜索) enables discovery teams to unlock challenging drug targets that have historically evaded drug discovery, thus accelerating discovery timelines and enabling new therapies," said Dr. Elmar Nurmemmedov, Co-Founder & CEO of CellarisBio (搜索).
Commercial Product Line Launch
The newly released MICRO-TAG (搜索) reagent product line includes three distinct kits:
- MICRO-TAG Cellular DEL Kit — for cellular DNA-encoded library discovery with real-time engagement readouts
- MICRO-TAG Real-Time Hit Validation Kit — for cellular target engagement-based hit validation and optimization
- MICRO-TAG Protein Complex Target Engagement Kit — for testing target engagement in protein-protein complexes
The MICRO-TAG (搜索) platform is scalable, automatable, and programmatically flexible, with compatibility for standard real-time detection systems. CellarisBio (搜索) will present MICRO-TAG at SLAS 2026 as an Innovation AveNEW exhibitor and Ignite Award finalist.
Company Background
CellarisBio (搜索) is a San Diego-based bio-tool company founded in 2023 by co-inventors Dr. Elmar Nurmemmedov and Dr. Ivan Babic. The company developed the patented MICRO-TAG (搜索) platform to enable real-time measurement of cellular drug-target engagement and is commercializing the technology through reagent products and technology licensing.